Premarin Alzheimer's Prevention Studies Urged; Treatment Trial Negative
Executive Summary
A trial finding no effect for Premarin in the treatment of Alzheimer's does not rule out a role for estrogen replacement therapy in prevention of the disease, Wyeth-Ayerst and the study authors pointed out.
You may also be interested in...
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo
Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo
More bad news for Prempro
Preliminary analysis from the Women's Health Initiative Memory Study evaluating the use of estrogen plus progestin on the development of dementia and mild cognitive impairment suggests negative results. "In contrast to previous work that suggested a beneficial effect on memory and cognition, the preliminary analyses of this arm of WHIMS suggest certain negative findings in a small percentage of the study participants," Wyeth said. An earlier National Institutes of Health-funded study found Wyeth's Premarin (conjugated estrogens) had no effect in the treatment of Alzheimer's disease (1"The Pink Sheet" Feb. 8, 2000, p. 8)...